Foresite Capital

Cullinan Oncology Completes $131.2 Million Series C Financing

Retrieved on: 
Thursday, December 17, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Baupost Group, Venrock, Investment, Service companies, Cullinan Oncology LLC, Foresite Capital

Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the closing of an oversubscribed $131.2 million Series C financing.

Key Points: 
  • Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the closing of an oversubscribed $131.2 million Series C financing.
  • The financing was led by Foresite Capital with participation from additional new investors: Boxer Capital of Tavistock Group; Eventide Asset Management; Nextech Invest; OrbiMed; Venrock Healthcare Capital Partners; Rock Springs Capital; BVF Partners, L.P.; and Logos Capital.
  • Existing investors, including MPM Capital, F2 Ventures, Cowen Healthcare Investments, The Baupost Group, Schooner Capital, as well as other institutions and individuals, also participated in the round.
  • Cullinan Oncology was formed to develop a diversified portfolio of single asset oncology opportunities through both internal and external means and to do so in a unique, cost-efficient model that leverages a central management team and shared services model to drive speed and efficiency.

Alisa Mall Named As Managing Director at Foresite Capital

Retrieved on: 
Tuesday, December 1, 2020
Professional services, Health, Other Health, Finance, Finance, Money, Economy, Foresite Capital, Investor

Foresite Capital, a life sciences investment firm that funds visionary healthcare entrepreneurs, today announced the hiring of Alisa Mall as managing director, corporate strategy.

Key Points: 
  • Foresite Capital, a life sciences investment firm that funds visionary healthcare entrepreneurs, today announced the hiring of Alisa Mall as managing director, corporate strategy.
  • At Foresite Capital, her responsibilities include corporate development, long-term capital strategy, investor relations, and ESG engagement.
  • Alisa is a star in the endowment & foundation community, said Jim Tananbaum, CEO and managing director of Foresite Capital.
  • Foresite Capitals portfolio comprises the next generation of companies that are reshaping healthcare, using the tools of data science to do so, said Alisa Mall.

Michael Rome, PhD Promoted to Managing Director at Foresite Capital

Retrieved on: 
Tuesday, May 19, 2020
Professional services, Health, Other Health, Finance, Foresite Capital, Steven Tananbaum

Foresite Capital, a life sciences investment firm that funds visionary healthcare entrepreneurs, today announced the promotion of Dr. Michael Rome to managing director.

Key Points: 
  • Foresite Capital, a life sciences investment firm that funds visionary healthcare entrepreneurs, today announced the promotion of Dr. Michael Rome to managing director.
  • Michael has a great sense for entrepreneurs and technology, and how to help them leverage our internal and external networks, said Jim Tananbaum, founder and managing director of Foresite Capital.
  • Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies.
  • Michael joins managing directors Jim Tananbaum, MD; Dorothy Margolskee, MD; Matt Buten; Brett Zbar, MD; Dennis Ryan; and Vikram Bajaj, PhD on the managing director team.